ClinicalTrials.gg
Not yet recruitingNCT07435584EVER-RECODEUpdated Feb 27, 2026

Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)

A Phase 1/2 interventional study of Everolimus (Afinitor) tablets in Colorectal Cancer, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing everolimus in Colorectal Neoplasms — 2 open to participants now, 2 under way, none of them phase 3. Everolimus · Colorectal Neoplasms.

Planned enrollment
7th of 10
38 · median 41
Started
2026
the only one that year
Phase 1/2
4 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 10 studies testing everolimus in Colorectal Neoplasms, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1/2, and was the 10th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 10 studies testing everolimus in Colorectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing everolimus in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, open-label, multicenter, single-arm Phase Ib/II study evaluating the safety and preliminary efficacy of everolimus in patients with CDK12-deficient refractory metastatic colorectal cancer.

Read the detailed description

Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related mortality. Patients with refractory disease who have progressed after standard systemic therapies have limited treatment options and poor clinical outcomes. Identification of molecularly defined subgroups that may benefit from targeted therapeutic strategies represents an important unmet clinical need.

Cyclin-dependent kinase 12 (CDK12) plays a role in transcriptional regulation of genes involved in DNA damage response and genomic stability. CDK12 deficiency has been reported in a small subset of colorectal cancers, estimated at approximately 3-5% of cases. This molecular alteration may confer distinct biological characteristics and potential therapeutic vulnerabilities. However, the clinical efficacy of mTOR inhibition in CDK12-deficient metastatic colorectal cancer has not been prospectively evaluated.

EVER-RECODE adopts a combined Phase Ib/II study design. Phase Ib Component Design: Prospective, multicenter, open-label, single-arm study utilizing a traditional 3+3 dose-escalation design.

Objectives:

  • Evaluate the safety and tolerability of everolimus in patients with CDK12-deficient refractory mCRC.
  • Determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D).

Planned dose levels include 5 mg/day, 7.5 mg/day, and 10 mg/day administered orally once daily in continuous dosing. Although 10 mg/day has been widely used in several solid tumors, everolimus is associated with dose-dependent toxicities, particularly mucosal and dermatologic adverse events that frequently occur during early treatment. To ensure patient safety in this refractory population, the study adopts 5 mg/day as the starting dose, with stepwise escalation under close safety monitoring to identify the optimal tolerated dose.

Phase II Component Design: Prospective, multicenter, open-label, single-arm expansion study.

Objective:

  • Evaluate the preliminary antitumor activity of everolimus at the RP2D in patients with CDK12-deficient refractory mCRC.

Study Procedures Eligible participants must have metastatic colorectal cancer with CDK12 deficiency confirmed by immunohistochemistry (IHC). Participants will receive continuous daily oral everolimus. Radiologic tumor assessments will be performed every 8 weeks. Participants will be followed for safety and survival for up to 24 months.

Primary Endpoints Phase Ib: Incidence of dose-limiting toxicities (DLTs) and determination of MTD/RP2D.

Phase II: Objective response rate (ORR) assessed according to RECIST version 1.1.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal cancer
  • CDK12
  • Everolimus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and voluntarily sign an ethics committee-approved form and willingness to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  2. Age 18 to 80 years (inclusive) at the time of signing informed consent; male or female.
  3. (ECOG) performance status of 0 or 1.
  4. Estimated ≥12 weeks.
  5. CDK12 deficiency confirmed by immunohistochemistry (IHC).
  6. confirmed colorectal cancer with documented disease progression after prior standard systemic antitumor therapies, including but not limited to oxaliplatin, fluoropyrimidine, and irinotecan.

    o Patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors must have experienced disease progression following /PD-L1 therapy.

  7. At least one according to version 1.1, defined as:

    • Non-nodal lesions ≥10 mm in longest diameter by CT scan (slice thickness ≤5 mm);
    • Malignant lymph nodes with short axis ≥15 mm by CT scan (slice thickness ≤5 mm recommended).
  8. Adequate organ function meeting all of the following criteria:

    Hematologic (without growth factor support or transfusion within 7 days prior to testing):

    • ≥1.5 × 10⁹/L
    • count ≥75 × 10⁹/L
    • ≥90 g/L

    Biochemical:

    • Total ≤1.5 × (ULN)
    • and ALT ≤2.5 × ULN
    • Serum creatinine ≤1.5 × ULN or ≥50 mL/min (calculated using Cockcroft-Gault formula)

    Coagulation:

    • (INR) ≤1.5
    • Activated partial thromboplastin time (aPTT or PTT) ≤1.5 × ULN
  9. Absence of high-risk conditions, including:

    • Active or major cardiovascular events within 6 months (e.g., myocardial infarction, severe heart failure, stroke);
    • Severe pulmonary dysfunction requiring long-term oxygen therapy or interstitial lung disease/pulmonary fibrosis;
    • Active uncontrolled infection (including uncontrolled , , , or tuberculosis);
    • Other active within 5 years, except those treated with curative local therapy.
  10. For participants of :

    • Must agree to use effective during the study and for 120 days after completion;
    • Negative serum pregnancy test within 7 days prior to enrollment;
    • Not breastfeeding.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

  1. Untreated or active central nervous system (CNS) . Patients with a history of or current leptomeningeal disease.
  2. Receipt of systemic antitumor therapy within 4 weeks prior to initiation of study treatment.

    • For prior small-molecule targeted therapy: the interval between the end of prior therapy and first study dose must be ≥5 half-lives of the drug or ≥7 days, whichever is longer.
    • For prior traditional Chinese antitumor medicines: ≥2 weeks is required.
  3. Palliative radiotherapy to non-target lesions, radioactive seed implantation, radiofrequency ablation, or similar local therapy within 28 days prior to first study dose.
  4. Toxicities or complications from prior therapies that have not recovered to grade ≤1 or to eligibility-specified levels.

    o Patients with stable grade ≤2 toxicities may be enrolled at investigator discretion if no safety risk exists (e.g., -related type 1 diabetes or hypothyroidism controlled with hormone replacement therapy).

  5. Within 28 days prior to first study dose: inability to swallow oral medication, chronic diarrhea, active gastroenteritis, gastrointestinal perforation, prior major gastrointestinal resection, colitis, or other conditions that may impair drug administration or absorption.
  6. Clinically symptomatic moderate or severe ascites requiring therapeutic paracentesis or drainage within 2 weeks prior to study treatment.

    • Small asymptomatic ascites detected by imaging is allowed.
    • Uncontrolled or moderate-to-large pleural effusion or pericardial effusion.
  7. Evidence of intestinal obstruction or signs/symptoms of obstruction at baseline.

    • Patients who underwent surgery with complete resolution of obstruction may be screened.
    • Presence of an indwelling intestinal stent at screening.
  8. Uncontrolled or severe cardiovascular disease, including:

    • Severe or unstable congestive heart failure ( class II-IV)
    • Myocardial infarction within 6 months prior to first dose
    • Unstable angina within 1 month prior to treatment
    • Unstable arrhythmia
  9. History of or concurrent other than colorectal cancer, unless in complete remission for ≥5 years prior to screening and not requiring ongoing therapy, except:

    • Basal cell carcinoma of the skin
    • Superficial bladder cancer
    • Cutaneous squamous cell carcinoma
    • Cervical carcinoma in situ
    • Localized prostate cancer
    • Ductal carcinoma in situ after curative surgery
    • Non-metastatic prostate or breast cancer receiving hormone therapy
  10. Severe infection within 28 days prior to first dose, including infections requiring hospitalization, bacteremia, or severe pneumonia.

    • Active infection requiring therapeutic intravenous antibiotics within 2 weeks prior to treatment.
    • Prophylactic antibiotics (e.g., for urinary tract infection prevention) are permitted.
  11. Active infection defined as:

    o Positive HBsAg AND HBV DNA ≥10,000 copies/mL (≥2,000 IU/mL).

    Active defined as:

    o Positive HCV antibody AND detectable HCV RNA.

  12. Active pulmonary tuberculosis within 1 year prior to enrollment, or history of active tuberculosis >1 year prior without appropriate standard treatment.
  13. Known immunodeficiency, including positivity, congenital or acquired immunodeficiency disorders, or history of organ transplantation.
  14. Active disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, myasthenia gravis, or requirement for long-term systemic therapy.
  15. Concomitant use of strong inhibitors or inducers that cannot be discontinued ≥7 days prior to first dose (e.g., ketoconazole, itraconazole, clarithromycin, rifampin, carbamazepine, phenobarbital).
  16. Active severe oral mucosal disease or recurrent oral ulceration.

    o History of ≥grade 2 stomatitis that has not recovered to CTCAE grade ≤1.

  17. Active dermatologic disorders (e.g., psoriasis, severe eczema, chronic pruritus) or prior ≥grade 2 drug-related skin reactions not fully resolved.
  18. Prior treatment with everolimus and:

    • Development of ≥grade 3 drug-related toxicity, OR
    • Discontinuation due to resistance or lack of efficacy.
  19. Known to everolimus or any of its metabolites.
  20. Pregnant or breastfeeding women, or women planning pregnancy during the study period.
  21. Uncontrolled psychiatric illness, known alcohol or drug abuse, incarceration, or other conditions that may interfere with study compliance.
  22. Any other condition that, in the investigator's judgment, may increase study risk, interfere with study outcomes, or make the participant unsuitable.
  23. Inability to understand study conditions and objectives or refusal to sign .
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Everolimus Treatment

    Participants with CDK12-deficient refractory metastatic colorectal cancer will receive oral everolimus once daily. Phase Ib will follow a traditional 3+3 dose-escalation design (5 mg, 7.5 mg, 10 mg, oral, daily) for 8 weeks to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Phase II will evaluate efficacy at the RP2D.

    Drug: Everolimus (Afinitor) tablets

Interventions

  • DrugEverolimusStudies of EverolimusEverolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Everolimus administered orally once daily in continuous treatment. Phase Ib dose levels include 5 mg/day, 7.5 mg/day, and 10 mg/day using a standard 3+3 dose-escalation design. Phase II participants will receive everolimus at the RP2D determined in Phase Ib.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    Dose-limiting toxicity (DLT) is defined as treatment-related toxicity occurring within the first 8 weeks (DLT observation window) that is assessed as definitely, probably, or possibly related to everolimus and meets any of the following criteria based on NCI-CTCAE version 5.0: * Grade ≥3 non-hematologic toxicity (excluding Grade 3 nausea/vomiting resolving within 48 hours with supportive care, Grade 3 alopecia, and Grade 3 fatigue without ECOG deterioration); * Grade 4 hematologic toxicity (including neutropenia lasting ≥7 days, thrombocytopenia with active bleeding, or hemoglobin \<60 g/L requiring urgent transfusion); * Grade 3 hematologic toxicity persisting ≥14 days without recovery to ≤Grade 2; * Treatment interruption ≥14 days due to drug-related toxicity; * Other toxicities considered by the investigator to significantly compromise patient safety. For Phase Ib study

    Time frame: First 8 weeks after initial dose

  2. Objective Response Rate (ORR)

    Proportion of participants achieving complete response (CR) or partial response (PR) according to RECIST version 1.1. For Phase II study

    Time frame: Assessed every 8 weeks up to 24 months

Secondary outcomes

  1. Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D)

    Determination of the highest dose level at which ≤1 of 6 participants experiences DLT during the first 8 weeks (3+3 design). For Phase Ib study

    Time frame: Up to 8 weeks

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Incidence and severity of adverse events graded according to NCI-CTCAE version 5.0. For Phase Ib and Phase II study

    Time frame: From first dose until end of treatment (up to 24 months)

  3. Progression-Free Survival (PFS)

    Time from first dose to disease progression per RECIST version 1.1 or death from any cause. For Phase II study

    Time frame: Up to 24 months

  4. Overall Survival (OS)

    Time from first dose to death from any cause. For Phase II study

    Time frame: Up to 24 months

  5. Disease Control Rate (DCR)

    Proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1.

    Time frame: Assessed every 8 weeks up to 24 months

  6. Duration of Response (DoR)

    Time from first documented response (CR or PR) to disease progression or death. For Phase II study

    Time frame: Up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — In accordance with the requirements of the International Committee of Medical Journal Editors, the de-identified raw data of this study will be made public after the results are published. The access method will be stated when the research results are published.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The access method will be stated when the research results are published.

Access criteria: To access the Individual Participant Data (IPD), a detailed data usage plan must be submitted, specifying the research objectives and study content, which will be approved following review by the Principal Investigator (PI) of this study.

Data sharing details ↗ · icstac.com.cn

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 9 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Feb 27, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07435584
Responsible party
Kong Xiangxing (Associate Chief Physician, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Principal investigator
First posted
Feb 27, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Xiangxing Kong
Contact
kongxiangxing@zju.edu.cn
+8615068803769
Jianqing YU
Contact
jianqingyu@zju.edu.cn
+8619521531205
Xiangxing Kong
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion